NCT03436498View on ClinicalTrials.gov

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 10, 2018

Primary Completion Date

October 6, 2018

Study Completion Date

October 6, 2018

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Insulin aspart SAR341402

"Pharmaceutical form: Solution~Route of administration: Subcutaneous"

DRUG

Insulin aspart

"Pharmaceutical form: Solution~Route of administration: Subcutaneous"

Trial Locations (3)

50265

Investigational Site Number 8400003, West Des Moines

72211

Investigational Site Number 8400001, Little Rock

80262

Investigational Site Number 8400002, Denver

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT03436498 - Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients | Biotech Hunter | Biotech Hunter